Gema is developing noninvasive human oocyte and embryo selection methods to fundamentally improve the prospects for in vitro fertilization.
For many people who want to start a family, the dream of having a child is not easily realized. Of those who can afford in vitro fertilization (IVF), only 30% succeed in giving birth. Gema's diagnostic tests will give IVF practitioners the tools they lack to be able to objectively and non-invasively select the healthiest, most-viable embryos, thereby dramatically improving the odds of clinical success.
Dave ReppChief Operating OfficerUnconfirmedMr. Repp has 15 years of experience in research commercialization, new venture creation, and business consulting in the life sciences and technology. He co-founded and was VP of Bus. Ops. for Avidimer Therapeutics a venture backed biotech developing targeted drug technologies. Mr. Repp holds an MBA (Samuel Zell Scholar) from the Ross School of Business at the University of Michigan and MS in Mechanical Engineering from the University of Michigan.
Jose CibelliFounder and Chief Scientific OfficerUnconfirmedDr. Cibelli is a pioneer in cloning with transgenic somatic cells and embryonic stem cells – he and his team generated the world's first transgenic cloned calves, the first embryonic stem cell line from humans by nuclear transfer, and the first embryonic stem cells by parthenogenesis in primates. Dr. Cibelli earned his PhD in Reproductive Physiology at the University of Massachusetts and his DVM from the University of La Plata.
Amy IagerDirector of Research & DevelopmentUnconfirmedMs. Iager has ten years of experience in embryology, molecular biology, and cell culture research. Ms. Iager earned her MS in Animal Biotechnology from Michigan State University with a focus on research in embryology and gene expression analyses in embryos.
North Coast Technology InvestorsUnconfirmed
The Dow Chemical CompanyUnconfirmed
Blue Water AngelsUnconfirmed